Cutaneous Squamous Cell Carcinoma (CSCC)Phase 2NCT07394244
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
A Phase 2 study testing Pucotenlimab and Becotatug Vedotin in people with Cutaneous Squamous Cell Carcinoma (CSCC), run by Fudan University at 1 site in China.
Trial summary
Study Design The study plans to enroll 38 patients. A Simon's two-stage design is employed. Based on historical data, the objective response rate (ORR) for patients meeting the inclusion criteria and receiving PD-1 inhibitor monotherapy is approximately 30%. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cutaneous Squamous Cell Carcinoma (CSCC)
- What is being tested?
- Pucotenlimab and Becotatug Vedotin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 1 siteChina
- Study dates
- 9 Jan 2026to 31 Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntarily sign the informed consent form and agree to comply with the protocol requirements.
- Age ≥18 years and ≤80 years on the day of signing the informed consent form, regardless of gender.
- Life expectancy ≥12 weeks.
- Histopathologically confirmed cutaneous squamous cell carcinoma (cSCC), which is either locally advanced and inoperable (including recurrence after ≥2 prior surgeries, or deemed unresectable by a surgeon, or where surgery may lead to severe complications or deformity) or metastatic.
- Have received 0-1 prior lines of systemic chemotherapy for advanced cSCC, and have experienced disease progression during or after the most recent treatment (relapse within 6 months after completing adjuvant therapy is considered as one line of therapy).
- Able to provide tumor tissue specimens (paraffin blocks, paraffin-embedded sections, or fresh tissue sections) from a primary or metastatic site for pathological testing. The most recent archived tumor tissue specimen should be used. If archived tissue is unavailable, a new biopsy must be performed.
Show all 14Show fewer
- Have at least one measurable lesion at baseline according to RECIST 1.1 criteria (the longest diameter ≥10 mm on CT scan, or short axis ≥15 mm for lymph nodes; measurable lesions should not have been irradiated, unless progression has been demonstrated within a prior radiation field or after local therapy). Digital photography may be used for superficial lesions.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to treatment initiation.
- No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to treatment initiation.
- Adequate organ function within 7 days prior to treatment initiation, defined as:
- (1)Bone Marrow Function: Absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet count ≥100×10⁹/L, hemoglobin ≥90 g/L; and no transfusion or blood product administration within 14 days prior to the first dose, and no treatment with biologic response modifiers (e.g., G-CSF, erythropoietin) within 7 days prior to the first dose.
- (2)Liver Function: For patients without liver metastases: total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN. For patients with liver metastases: TBIL ≤1.5 × ULN, ALT and AST ≤5 × ULN.
- (3)Renal Function: Serum creatinine (Cr) ≤1.5 × ULN, or creatinine clearance (Ccr) ≥50 mL/min (calculated using the Cockcroft-Gault formula) (4)Coagulation Function: International normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN (unless the patient is receiving therapeutic anticoagulation).
- 11.Men and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational product. Women of childbearing potential include premenopausal women and women within 2 years of menopause. A negative serum pregnancy test result is required for women of childbearing potential within ≤7 days before the first dose of the investigational product.
Who cannot join
- History of other malignancies within the past five years, except for cured cervical carcinoma in situ, thyroid cancer, or cutaneous basal cell carcinoma.
- Prior receipt of any of the following treatments:
- Any prior therapy targeting anti-PD-1, anti-PD-L1, PD-L2, CD137, CTLA-4 antibodies, or any other antibodies/drugs specifically targeting T-cell costimulation or immune checkpoint pathways;
- Any prior EGFR monoclonal antibody therapy;
- Investigational drug administration within 28 days before the first dose;
- Anticancer chemotherapy within 21 days before the first dose (washout period ≥14 days for oral fluoropyrimidines, leucovorin, or weekly paclitaxel chemotherapy; ≥42 days for nitrosoureas or mitomycin);
Show all 21Show fewer
- Radiotherapy within 28 days before the first dose, or palliative radiotherapy for bone metastases within 2 weeks;
- Major surgery within 28 days before the first dose without full recovery, or planned major surgery within the first 12 weeks after receiving the study drug.
- Symptomatic brain or leptomeningeal metastases (unless treated >6 months prior, with negative imaging within 4 weeks before enrollment, and stable neurological status without steroid therapy).
- Any severe or uncontrolled systemic disease per investigator's judgment, including poorly controlled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg), uncontrolled diabetes, or active bleeding signs.
- Poorly controlled cardiac diseases, including NYHA Class II or higher heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular/ventricular arrhythmias requiring treatment.
- Active infections, including:
- Hepatitis B (HBsAg-positive AND HBV DNA ≥2000 IU/mL, excluding drug-induced or other non-viral hepatitis);
- Hepatitis C (anti-HCV antibody-positive AND HCV RNA above the lower limit of detection);
- HIV infection; or uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infections (unless treated and resolved before study drug initiation).
- History of hypersensitivity to any component of Pucotenlimab or Vebreltus (e.g., histidine, histidine hydrochloride, sucrose, mannitol, polysorbate 80), or ≥Grade 3 allergic reactions to macromolecular protein preparations/monoclonal antibodies.
- Primary immunodeficiency history or active autoimmune disease requiring immunosuppressants or systemic glucocorticoids (dose ≥10 mg/day prednisone or equivalent within 2 weeks before enrollment).
- Note: Patients with type I diabetes, stable hypothyroidism on hormone replacement, psoriasis/eczema not requiring systemic therapy, or vitiligo may be enrolled. Topical/inhaled corticosteroids or short-term (≤7 days) glucocorticoid use for non-autoimmune conditions are exempted.
- History or presence of interstitial lung disease, radiation pneumonitis, severe chronic obstructive pulmonary disease, severe respiratory insufficiency, or symptomatic bronchospasm.
- Positive serum pregnancy test, lactation, or unwillingness to use adequate contraception during the study and for 6 months after the last dose.
- Other conditions deemed inappropriate for participation by the investigator (e.g., alcohol/drug abuse).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Fudan University Shanghai Cencer Center, Shanghai, Shanghai
Shanghai, 200032
Zhiguo Luo, MD, 862164175590, luozhiguo88@163.com
About this study
Official title: Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma: A Single-Arm, Multicenter, Prospective Phase II Clinical Trial
Study Design The study plans to enroll 38 patients. A Simon's two-stage design is employed. Based on historical data, the objective response rate (ORR) for patients meeting the inclusion criteria and receiving PD-1 inhibitor monotherapy is approximately 30%. The expected ORR for the combination of Pucotenlimab and Vebreltus is 55%. With a one-sided α=0.05 and 80% power, 9 patients will be enrolled in the first stage. If ≥2 patients achieve a partial response (PR) or complete response (CR), the study will proceed to the second stage. An additional 25 patients will be enrolled in the second stage, resulting in a total of 34 patients. If ≥15 patients in the total population achieve a PR, the study endpoint is considered met. Accounting for a 10% dropout rate, a total of 38 patients will be enrolled.
Study Procedures After providing full informed consent and passing screening, eligible subjects will receive treatment with Vebreltus 2.0 mg/kg and Pucotenlimab 200 mg. On the first day of each treatment cycle, patients will receive an intravenous infusion of Pucotenlimab (infusion duration: 60 min ± 15 min, with the first cycle infusion lasting no less than 60 minutes). At least 30 minutes after the completion of the Pucotenlimab infusion, the Vebreltus infusion will commence (infusion duration: 60 min ± 15 min, with the first cycle infusion lasting no less than 60 minutes). Patients will receive the combination therapy once every 3 weeks until completion of 2 years of treatment or until the occurrence of a protocol-defined treatment discontinuation event. Following the end of treatment, each subject will undergo a 30-day (+7 days) safety follow-up to monitor adverse events and clinically relevant events. Post-treatment survival follow-up will be conducted every 12 weeks (±7 days). For subjects who discontinue treatment for reasons other than disease progression/death and do not initiate new anti-cancer therapy, tumor imaging assessments will continue per the original schedule until disease progression, initiation of new anti-cancer therapy, withdrawal of consent, loss to follow-up, or death, whichever occurs first.
Read more
After enrollment, tumor response will be assessed according to RECIST v1.1 and iRECIST criteria. Imaging evaluations will be performed every 6 weeks (±7 days) from the first dose for the first 54 weeks, and then every 9 weeks (±7 days) thereafter (regardless of any delays in study drug administration), until iRECIST-confirmed progressive disease (iPD), initiation of new anti-cancer therapy, withdrawal of informed consent, loss to follow-up, or death, whichever occurs first.
Exploratory Analysis This study will analyze the correlation between biomarkers in patient tumor tissue/blood samples (e.g., EGFR expression, PD-L1 CPS score, TILs) collected before and after treatment and clinical efficacy endpoints (e.g., ORR, PFS, DoR).
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Being tested
- Pucotenlimab, Becotatug Vedotin
- Keywords
- Becotatug Vedotin, Pucotenlimab, CSCC, EGFR-ADC
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PucotenlimabDrug
Also called HX008
The medications are administered via intravenous infusion. Pucotenlimab is given at a fixed dose of 200 mg, The infusion time is 60 ± 15 minutes (if infusion-related reactions occur, the infusion duration may be extended, up to a maximum of 4 hours). Dosing occurs on the first day of each 3-week cycle (Q3W). Pucotenlimab should be given first. For the first cycle, the infusion time for both drugs must not be less than 60 minutes.
Becotatug VedotinDrug
Also called MRG003
The medications are administered via intravenous infusion. Becotatug Vedotin is dosed at 2.0 mg/kg based on the patient's actual body weight. The infusion time for Becotatug Vedotin is 60 ± 15 minutes (if infusion-related reactions occur, the infusion duration may be extended, up to a maximum of 4 hours). Dosing occurs on the first day of each 3-week cycle (Q3W). The infusion of Becotatug Vedotin should start at least 30 minutes after the completion of the Pucotenlimab infusion. For the first cycle, the infusion time must not be less than 60 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Experimental: Becotatug Vedotin+Pucotenlimab | Experimental | The medications are administered via intravenous infusion. Pucotenlimab is given at a fixed dose of 200 mg, and Becotatug Vedotin is dosed at 2.0 mg/kg based on the patient's actual body weight. The infusion time for each drug is 60 ± 15 minutes (if infusion-related reactions occur, the infusion duration may be extended, up to a maximum of 4 hours). Dosing occurs on the first day of each 3-week cycle (Q3W). Pucotenlimab and Vebreltus are administered on the same day, with Pucotenlimab given first. The infusion of Vebreltus should start at least 30 minutes after the completion of the Pucotenlimab infusion. For the first cycle, the infusion time for both drugs must not be less than 60 minutes. Receives: Drug: Pucotenlimab; Drug: Becotatug Vedotin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate
ORR is defined as the proportion of subjects achieving confirmed Complete Response (CR) or Partial Response (PR) as assessed by the investigator according to RECIST v1.1 and iRECIST criteria. ORR analysis will be based on the Full Analysis Set (FAS)
Measured: up to 2 years
Secondary outcomes (4)
Disease Control Rate
Disease Control Rate (DCR) is defined as the proportion of subjects assessed by the Independent Review Committee (IRC) according to RECIST v1.1 criteria who achieve CR, PR, or Stable Disease (SD) (lasting for at least 6 weeks from the first dose), along with the exact 95% CI using the Clopper-Pearson method.
Measured: up to 2 years
Progression-Free Survival
Progression-Free Survival (PFS) is defined as the time from enrollment to the first occurrence of disease progression or death from any cause. For subjects without observed progression or death, PFS will be censored at the time of the last valid and adequate assessment. PFS analysis will be based on the FAS. The median PFS and its 95% CI will be estimated using the Kaplan-Meier method, and progression-free survival curves will be generated.
Measured: up to 2 years
Duration of Response
Duration of Response (DOR) is defined as the time from the first documented evidence of response (PR or CR according to RECIST v1.1 and iRECIST criteria, whichever is later) to the first documented disease progression (PD) or death from any cause, whichever occurs first, in subjects with a confirmed response. For subjects without observed progression or death, DOR will be censored at the time of the last adequate tumor assessment. DOR analysis will be performed on subjects who achieve CR or PR. The median DOR and its 95% CI will be estimated using the Kaplan-Meier method, and duration of response curves will be generated.
Measured: up to 2 years
Overall Survival
Overall Survival (OS) is defined as the time from enrollment to death from any cause. For subjects not followed up to death, OS will be censored at the time of the last valid survival follow-up. Based on the FAS, the median OS (if applicable) and its 95% CI will be estimated using the Kaplan-Meier method, and survival curves will be plotted.
Measured: up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2026
- Study start9 Jan 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cutaneous Squamous Cell Carcinoma (CSCC)Studies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Collaborators
- Lepu Biopharma Co., Ltd.
- Responsible party
- Principal investigator, Zhiguo Luo, MD, PhD, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07394244
- Sponsor's protocol ID
- Fudan CSCC-01
- Status last verified
- Feb 2026
- First submitted
- 19 Jan 2026
- Last updated
- 6 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma: A Single-Arm, Multicenter, Prospective Phase II Clinical Trial
- ClinicalTrials.gov ID
- NCT07394244
- Acronym / sponsor ID
- Fudan CSCC-01
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Keywords
- Becotatug Vedotin, Pucotenlimab, CSCC, EGFR-ADC
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Collaborators
- Lepu Biopharma Co., Ltd.
- Study start
- 9 Jan 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 6 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study Design The study plans to enroll 38 patients. A Simon's two-stage design is employed. Based on historical data, the objective response rate (ORR) for patients meeting the inclusion criteria and receiving PD-1 inhibitor monotherapy is approximately 30%. The expected ORR for the combination of Pucotenlimab and Vebreltus is 55%. With a one-sided α=0.05 and 80% power, 9 patients will be enrolled in the first stage. If ≥2 patients achieve a partial response (PR) or complete response (CR), the study will proceed to the second stage. An additional 25 patients will be enrolled in the second stage, resulting in a total of 34 patients. If ≥15 patients in the total population achieve a PR, the study endpoint is considered met. Accounting for a 10% dropout rate, a total of 38 patients will be enrolled.
Study Procedures After providing full informed consent and passing screening, eligible subjects will receive treatment with Vebreltus 2.0 mg/kg and Pucotenlimab 200 mg. On the first day of each treatment cycle, patients will receive an intravenous infusion of Pucotenlimab (infusion duration: 60 min ± 15 min, with the first cycle infusion lasting no less than 60 minutes). At least 30 minutes after the completion of the Pucotenlimab infusion, the Vebreltus infusion will commence (infusion duration: 60 min ± 15 min, with the first cycle infusion lasting no less than 60 minutes). Patients will receive the combination therapy once every 3 weeks until completion of 2 years of treatment or until the occurrence of a protocol-defined treatment discontinuation event. Following the end of treatment, each subject will undergo a 30-day (+7 days) safety follow-up to monitor adverse events and clinically relevant events. Post-treatment survival follow-up will be conducted every 12 weeks (±7 days). For subjects who discontinue treatment for reasons other than disease progression/death and do not initiate new anti-cancer therapy, tumor imaging assessments will continue per the original schedule until disease progression, initiation of new anti-cancer therapy, withdrawal of consent, loss to follow-up, or death, whichever occurs first.
After enrollment, tumor response will be assessed according to RECIST v1.1 and iRECIST criteria. Imaging evaluations will be performed every 6 weeks (±7 days) from the first dose for the first 54 weeks, and then every 9 weeks (±7 days) thereafter (regardless of any delays in study drug administration), until iRECIST-confirmed progressive disease (iPD), initiation of new anti-cancer therapy, withdrawal of informed consent, loss to follow-up, or death, whichever occurs first.
Exploratory Analysis This study will analyze the correlation between biomarkers in patient tumor tissue/blood samples (e.g., EGFR expression, PD-L1 CPS score, TILs) collected before and after treatment and clinical efficacy endpoints (e.g., ORR, PFS, DoR).
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental: Becotatug Vedotin+Pucotenlimab | Experimental | Drug: Pucotenlimab, Drug: Becotatug VedotinThe medications are administered via intravenous infusion. Pucotenlimab is given at a fixed dose of 200 mg, and Becotatug Vedotin is dosed at 2.0 mg/kg based on the patient's actual body weight. The infusion time for each drug is 60 ± 15 minutes (if infusion-related reactions occur, the infusion duration may be extended, up to a maximum of 4 hours). Dosing occurs on the first day of each 3-week cycle (Q3W). Pucotenlimab and Vebreltus are administered on the same day, with Pucotenlimab given first. The infusion of Vebreltus should start at least 30 minutes after the completion of the Pucotenlimab infusion. For the first cycle, the infusion time for both drugs must not be less than 60 minutes. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Voluntarily sign the informed consent form and agree to comply with the protocol requirements.
- Age ≥18 years and ≤80 years on the day of signing the informed consent form, regardless of gender.
- Life expectancy ≥12 weeks.
- Histopathologically confirmed cutaneous squamous cell carcinoma (cSCC), which is either locally advanced and inoperable (including recurrence after ≥2 prior surgeries, or deemed unresectable by a surgeon, or where surgery may lead to severe complications or deformity) or metastatic.
- Have received 0-1 prior lines of systemic chemotherapy for advanced cSCC, and have experienced disease progression during or after the most recent treatment (relapse within 6 months after completing adjuvant therapy is considered as one line of therapy).
Key exclusion criteria (21 listed)
- History of other malignancies within the past five years, except for cured cervical carcinoma in situ, thyroid cancer, or cutaneous basal cell carcinoma.
- Prior receipt of any of the following treatments:
- Symptomatic brain or leptomeningeal metastases (unless treated >6 months prior, with negative imaging within 4 weeks before enrollment, and stable neurological status without steroid therapy).
- Any severe or uncontrolled systemic disease per investigator's judgment, including poorly controlled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg), uncontrolled diabetes, or active bleeding signs.
- Poorly controlled cardiac diseases, including NYHA Class II or higher heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular/ventricular arrhythmias requiring treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PucotenlimabAlso: HX008The medications are administered via intravenous infusion. Pucotenlimab is given at a fixed dose of 200 mg, The infusion time is 60 ± 15 minutes (if infusion-related reactions occur, the infusion duration may be extended, up to a maximum of 4 hours). Dosing occurs on the first day of each 3-week cycle (Q3W). Pucotenlimab should be given first. For the first cycle, the infusion time for both drugs must not be less than 60 minutes. | Drug | Experimental: Becotatug Vedotin+Pucotenlimab |
| Becotatug VedotinAlso: MRG003The medications are administered via intravenous infusion. Becotatug Vedotin is dosed at 2.0 mg/kg based on the patient's actual body weight. The infusion time for Becotatug Vedotin is 60 ± 15 minutes (if infusion-related reactions occur, the infusion duration may be extended, up to a maximum of 4 hours). Dosing occurs on the first day of each 3-week cycle (Q3W). The infusion of Becotatug Vedotin should start at least 30 minutes after the completion of the Pucotenlimab infusion. For the first cycle, the infusion time must not be less than 60 minutes. | Drug | Experimental: Becotatug Vedotin+Pucotenlimab |
Primary outcome
Objective Response Rate
Time frame: up to 2 years
ORR is defined as the proportion of subjects achieving confirmed Complete Response (CR) or Partial Response (PR) as assessed by the investigator according to RECIST v1.1 and iRECIST criteria. ORR analysis will be based on the Full Analysis Set (FAS)
4 secondary outcomes
Disease Control Rate
Time frame: up to 2 years
Progression-Free Survival
Time frame: up to 2 years
Duration of Response
Time frame: up to 2 years
Overall Survival
Time frame: up to 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Cutaneous Squamous Cell Carcinoma (CSCC)
Active, not recruitingPhase 2
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Squamous Cell Carcinoma
RecruitingEarly Phase 1
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
Not yet recruitingPhase 2
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC)
RecruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (CSCC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pucotenlimab and Becotatug Vedotin in people with Cutaneous Squamous Cell Carcinoma (CSCC), run by Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xin Liu, MD (+86 13761503356, jeanettexin@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Response Rate (time frame: up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2026.